Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

EMERYVILLE, Calif. , Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m.

PRNewsWire • Nov 19, 2025

Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript

Dynavax Technologies Corporation ( DVAX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Cox - VP of Investor Relations & Corporate Communications Ryan Spencer - CEO & Director Donn Casale - Senior VP & Chief Commercial Officer Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Kelly MacDonald - Senior VP & CFO Conference Call Participants Matthew Phipps - William Blair & Company L.L.C., Research Division Philip Nadeau - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Third Quarter 2025 Financial Results Conference Call.

Seeking Alpha • Nov 6, 2025

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunities Conference call today at 4:30 p.m. ET/1:30 p.m.

PRNewsWire • Nov 5, 2025

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA ; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued clinical development and commercialization following Phase 2b clinical development Vaxart will receive a $25 million upfront payment and a $5 million equity investment from Dynavax, along with additional potential milestone-based payments and royalties contingent on Dynavax advancing the program post-Phase 2b data readout EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif.

PRNewsWire • Nov 5, 2025

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

EMERYVILLE, Calif. , Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.

PRNewsWire • Oct 22, 2025

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older EMERYVILLE, Calif. , Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025.

PRNewsWire • Oct 21, 2025

3 Of My Favorite Biotech Stocks Under $10

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

Seeking Alpha • Sep 29, 2025

Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m.

PRNewsWire • Aug 27, 2025

Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral vaccine response rate at the dose selected for advancement, with comparable immunogenicity to Shingrix Dynavax selects the optimal dose of Z-1018 for advancement to Part 2 of Phase 1/2 trial in adults 70 years of age and older, expected to initiate in 2H 2025 EMERYVILLE, Calif. , Aug. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced positive topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years.

PRNewsWire • Aug 21, 2025